Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: From discovery to clinical proof of concept
Once-weekly dosing with eloralintide, an AMY1R-selective agonist, may offer a promising new therapeutic with favorable gastrointestinal tolerability for the treatment of obesity.
Authors
- Julie S. Moyers (ORCID: https://orcid.org/0000-0003-1779-1390)
- Minxia M. He
- Lai Tham (ORCID: https://orcid.org/0000-0002-1249-8526)
- David Allen (ORCID: https://orcid.org/0000-0002-8575-9547)
- Katherine Lansu (ORCID: https://orcid.org/0000-0002-1238-4940)
- Axel Haupt (ORCID: https://orcid.org/0000-0003-4502-0470)
- Daniel A. Briere
- Tamer Coşkun (ORCID: https://orcid.org/0000-0002-2481-133X)
- Kieren J. Mather (ORCID: https://orcid.org/0000-0001-8696-7500)
- Jorge Alsina‐Fernandez
- Libbey S. O′Farrell (ORCID: https://orcid.org/0000-0002-2825-5270)
- Hongchang Qu (ORCID: https://orcid.org/0000-0002-9835-3503)
- Beth Tidemann‐Miller
- Byron D. Bowen
- Edward Pratt (ORCID: https://orcid.org/0000-0003-4449-6231)
- Andrew Long (ORCID: https://orcid.org/0000-0001-8198-5937)
- Shobha Bhattachar
- Hilda Ibriga
Institutions
- Eli Lilly (United States) (US)
Publication Details
- Journal
- Molecular Metabolism
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1016/j.molmet.2025.102271
- Citations
- 10
- Primary Topic
- Diet, Metabolism, and Disease
- Type
- article
- Field-Weighted Citation Impact
- 12.95